By contrast, APRIL only signals through TACI and BCMA. Accordingly, anti-BAFF antibodies (belimumab) or BAFF-R–Ig provide selective BAFF blockade, whereas a TACI decoy receptor (TACI–Ig fusion ...

At present, dozens of BCMA-targeting therapies — such as chimeric antigen receptor T (CAR-T) cells, bi-specific antibodies and ... Immobilized Human BAFF, Fc Tag at 5 μg/mL (100 μL/well ...

Disclosure: The author declared no competing interests. A number of monoclonal antibodies or fusion proteins directed against B-cell surface molecules and trophic factors are currently in clinical ...

Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation ...